137 related articles for article (PubMed ID: 30992165)
21. Analogues of 4-[(7-Bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methylprop-2-ynylamino]-N-(3-pyridylmethyl)benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt).
Lockman JW; Murphy BR; Zigar DF; Judd WR; Slattum PM; Gao ZH; Ostanin K; Green J; McKinnon R; Terry-Lorenzo RT; Fleischer TC; Boniface JJ; Shenderovich M; Willardsen JA
J Med Chem; 2010 Dec; 53(24):8734-46. PubMed ID: 21080724
[TBL] [Abstract][Full Text] [Related]
22. Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
Travelli C; Aprile S; Rahimian R; Grolla AA; Rogati F; Bertolotti M; Malagnino F; di Paola R; Impellizzeri D; Fusco R; Mercalli V; Massarotti A; Stortini G; Terrazzino S; Del Grosso E; Fakhfouri G; Troiani MP; Alisi MA; Grosa G; Sorba G; Canonico PL; Orsomando G; Cuzzocrea S; Genazzani AA; Galli U; Tron GC
J Med Chem; 2017 Mar; 60(5):1768-1792. PubMed ID: 28165742
[TBL] [Abstract][Full Text] [Related]
23. Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.
Gunzner-Toste J; Zhao G; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Fu B; Han B; Ho YC; Kley N; Liang X; Liederer BM; Lin J; Mukadam S; O'Brien T; Oh A; Reynolds DJ; Sharma G; Skelton N; Smith CC; Sodhi J; Wang W; Wang Z; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X; Bair KW; Dragovich PS
Bioorg Med Chem Lett; 2013 Jun; 23(12):3531-8. PubMed ID: 23668988
[TBL] [Abstract][Full Text] [Related]
24. Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition.
Akiu M; Tsuji T; Sogawa Y; Terayama K; Yokoyama M; Tanaka J; Asano D; Sakurai K; Sergienko E; Sessions EH; Gardell SJ; Pinkerton AB; Nakamura T
Bioorg Med Chem Lett; 2021 Jul; 43():128048. PubMed ID: 33887438
[TBL] [Abstract][Full Text] [Related]
25. Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
Zak M; Yuen PW; Liu X; Patel S; Sampath D; Oeh J; Liederer BM; Wang W; O'Brien T; Xiao Y; Skelton N; Hua R; Sodhi J; Wang Y; Zhang L; Zhao G; Zheng X; Ho YC; Bair KW; Dragovich PS
J Med Chem; 2016 Sep; 59(18):8345-68. PubMed ID: 27541271
[TBL] [Abstract][Full Text] [Related]
26. Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
Biniecka P; Matsumoto S; Belotti A; Joussot J; Bai JF; Majjigapu SR; Thoueille P; Spaggiari D; Desfontaine V; Piacente F; Bruzzone S; Cea M; Decosterd LA; Vogel P; Nencioni A; Duchosal MA; Nahimana A
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838885
[TBL] [Abstract][Full Text] [Related]
27. Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors.
Tanuma SI; Katsuragi K; Oyama T; Yoshimori A; Shibasaki Y; Asawa Y; Yamazaki H; Makino K; Okazawa M; Ogino Y; Sakamoto Y; Nomura M; Sato A; Abe H; Nakamura H; Takahashi H; Tanuma N; Uchiumi F
Molecules; 2020 Aug; 25(16):. PubMed ID: 32785052
[TBL] [Abstract][Full Text] [Related]
28. Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors.
Sadrerafi K; Mason EO; Lee MW
Drug Des Devel Ther; 2018; 12():987-995. PubMed ID: 29731606
[TBL] [Abstract][Full Text] [Related]
29. Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
Ozgencil F; Eren G; Ozkan Y; Guntekin-Ergun S; Cetin-Atalay R
Bioorg Med Chem; 2020 Jan; 28(1):115217. PubMed ID: 31818629
[TBL] [Abstract][Full Text] [Related]
30. Fragment-based discovery of a potent NAMPT inhibitor.
Korepanova A; Longenecker KL; Pratt SD; Panchal SC; Clark RF; Lake M; Gopalakrishnan SM; Raich D; Sun C; Petros AM
Bioorg Med Chem Lett; 2018 Feb; 28(3):437-440. PubMed ID: 29287958
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitors using computational approaches.
Kesherwani M; Raghavan S; Gunasekaran K; Velmurugan D
J Biomol Struct Dyn; 2018 Apr; 36(5):1306-1328. PubMed ID: 28514875
[TBL] [Abstract][Full Text] [Related]
32. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.
Galli U; Travelli C; Massarotti A; Fakhfouri G; Rahimian R; Tron GC; Genazzani AA
J Med Chem; 2013 Aug; 56(16):6279-96. PubMed ID: 23679915
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
34. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI
Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909
[TBL] [Abstract][Full Text] [Related]
35. Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT.
Wang X; Xu TY; Liu XZ; Zhang SL; Wang P; Li ZY; Guan YF; Wang SN; Dong GQ; Zhuo S; Le YY; Sheng CQ; Miao CY
Sci Rep; 2015 Jul; 5():12657. PubMed ID: 26227784
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
Wang XY; Wang JZ; Gao L; Zhang FY; Wang Q; Liu KJ; Xiang B
Toxicol Appl Pharmacol; 2017 Sep; 331():54-61. PubMed ID: 28501332
[TBL] [Abstract][Full Text] [Related]
37. Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer.
Bai JF; Majjigapu SR; Sordat B; Poty S; Vogel P; Elías-Rodríguez P; Moreno-Vargas AJ; Carmona AT; Caffa I; Ghanem M; Khalifa A; Monacelli F; Cea M; Robina I; Gajate C; Mollinedo F; Bellotti A; Nahimana A; Duchosal M; Nencioni A
Eur J Med Chem; 2022 Sep; 239():114504. PubMed ID: 35724566
[TBL] [Abstract][Full Text] [Related]
38. Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen.
Palacios DS; Meredith E; Kawanami T; Adams C; Chen X; Darsigny V; Geno E; Palermo M; Baird D; Boynton G; Busby SA; George EL; Guy C; Hewett J; Tierney L; Thigale S; Weihofen W; Wang L; White N; Yin M; Argikar UA
Bioorg Med Chem Lett; 2018 Feb; 28(3):365-370. PubMed ID: 29275937
[TBL] [Abstract][Full Text] [Related]
39. Improved synthesis of MC4-PPEA and the biological evaluation of its hydroxymethyl derivative.
Sadrerafi K; Zargham EO; Lee MW
Bioorg Med Chem Lett; 2016 Jan; 26(2):618-621. PubMed ID: 26681512
[TBL] [Abstract][Full Text] [Related]
40. Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
Travelli C; Aprile S; Mattoteia D; Colombo G; Clemente N; Scanziani E; Terrazzino S; Alisi MA; Polenzani L; Grosa G; Genazzani AA; Tron GC; Galli U
Eur J Med Chem; 2019 Nov; 181():111576. PubMed ID: 31400709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
